This study will be a 12 weeks, douled blind, placebo-controlled, parallel group study of Fingerroot(Bosenbergia pandurata) for assessmenet of weight loss, body fat mass and fat percentage loss. This study will suggest the optimal intake and intake method and also will be based on a commercialization after acquired product-specific health functional food ingredients recognition and approval from KFDA(Korean Food & Drug Administration).1.Primary endpoints :Change in body weight at 4 weeks, 8 weeks, and 12 weeks
:Change of fat mass(kg), fat percentage(%) by DEXA from baseline at 12 weeks. 2.Secondary endpoints :The Comparison of safety for efficacy, adverse event(AE) clinical laboratory on the changes visceral fat, subcutaneous fat(by CT), and waist circumference from baseline at 12 weeks. 

 Supportive Care

Subjects will be randomized to receive Fingerroot(Bosenbergia pandurata) 300mg, 600mg or placebo. Subjets will orally self-adminster Fingerroot(Bosenbergia pandurata) 300mg, 600mg or placebo qd, 4 tablets per a day for 12weeks. 

Arm Label

Target Number of Participant

Arm Type

Arm Description

Subjets will take orally self-administer Fingerroot(Bosenbergia pandurata) 300mg qd, for 12weeks. 

Arm Label

Target Number of Participant

Arm Type

Arm Description

Subjets will take orally self-administer Fingerroot(Bosenbergia pandurata) 600mg qd, for 12weeks. 

Arm Label

Target Number of Participant

Arm Type

Arm Description

Subjets will take orally self-administer placebo qd, for 12weeks. 

Gender

Age

Description

1) Male and female subjects between 20-65years of age inclusive.
2) BMI of 25.0-29.9kg/m2 
3) Evidense of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial. 

1. Subjects with systolicBP ≥ 160 mmHg or diastolicBP ≥ 100 mmHg and also taking a beta blocker or a hydragogue.
2. Subjects with diabetes(use of hypoglycemic agent or insulin)or fasting blood glucose ≥ 126 mg/dL or random blood glucose ≥ 200 mg/dL.
3. Subjects with endocrinopathy or abnormal screening TSH value(≤0.1uU/ml or ≥10 uU/ml).
4. Serum AST/ALT ≥ 3 times the upper limit of normal. 
5. Serum creatinine ≥ 2 times the upper limit of normal. 
6. Use of prescription drugs or supplements known to alter body weight or appetite, antidepressants, oral contraceptive, steroid, female sex hormon. 
7. Subjets with clinically significant cardiovascular disease within the 6 months prior to screening. 
8. Subjets with a history of cancer and intervention within the 5 years prior to screening. 
9. Subjects with a history of CNS disorder(depressivedisorder,schizophrenia, alcoholism, drug addiction).
10. Women of childbearing age who are disagreed with effective contraceptions in the clinical trial period. 
11. Woman who are pregnant or lactating. 
12. Participation in any clinical trial within the 3 months prior to screening. 
13. Subjects with bleeding risk factor of stomach.
14. Subjects with the musculoskeletal disorders or restricted physical activity.
15. Subjects who could affect preclude evauation of response in the opinion investigator. 

Change in body weight 

From baseline at 12 weeks 

Chainge in fat percentage(by DEXA) 

From baseline at 12 weeks 

Chainge in fat mass(by DEXA) 

From baseline at 12 weeks 

Change in visceral fat(by CT) 

From baseline at 12weeks 

Change in subcutaneous fat(by CT) 

From baseline at 12weeks 

Change in waist circumference 

From baseline at 12weeks